Endogenous melatonin partial metabolic clearance as a potential endogenous marker of CYP1A2 activity
British Journal of Clinical Pharmacology · 2026-08 · 92 (8) · 2899-2908
DOI: 10.1002/bcp.70589 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 30.04.2026. Verfasst von Akitomo Yokokawa und 5 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Clinical Pharmacy and Experimental Therapeutics, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan. Hauptthemen laut MEDLINE: Melatonin, Cytochrome P-450 CYP1A2, Caffeine. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Aims
Cytochrome P450 1A2 (CYP1A2) exhibits substantial interindividual variability, necessitating appropriate phenotyping strategies for personalized pharmacotherapy. This study evaluated endogenous melatonin partial metabolic clearance (CL m(MEL) ), calculated from urinary 6‐hydroxymelatonin (6‐O‐MEL) excretion and plasma melatonin (MEL) exposure, as a potential endogenous marker of CYP1A2 activity and compared it with caffeine (CA)‐based indexes.
Methods
Eighteen healthy adults received 142–146 mg of CA following 48 h of CA abstinence. Blood samples were collected at 4, 6, 24 and 26 h post‐dose, and urine was collected over two 2‐h intervals (4–6 and 24–26 h). CA clearance (CL CA ) was derived from the plasma CA AUC using noncompartmental analysis, and CL m(MEL) was calculated as urinary 6‐hydroxymelatonin excretion divided by the corresponding plasma melatonin AUC.
Results
Mean CL CA was 4.71 ± 2.97 L/h. CL m(MEL) values were comparable between sampling intervals (54.65 ± 15.87 vs . 53.66 ± 25.81 L/h) and showed significant correlations with CL CA ( r = 0.57 and 0.67) and plasma paraxanthine/CA (PX/CA) ratios ( r = 0.63 and 0.65).
Conclusions
Endogenous CL m(MEL) correlates with established caffeine‐derived CYP1A2 phenotyping indexes and may represent a probe‐free approach for CYP1A2 phenotyping. Further validation under CYP1A2 induced and inhibited conditions is warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Clinical Pharmacy and Experimental Therapeutics, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan.
ORCID-Profile: Akitomo Yokokawa, Hiromi Shibasaki
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Yokokawa, A., Shimazaki, H., Igarashi, S., Tagawa, Y., Hisada, N., & Shibasaki, H. (2026). Endogenous melatonin partial metabolic clearance as a potential endogenous marker of CYP1A2 activity. British Journal of Clinical Pharmacology, 92(8), 2899-2908. https://doi.org/10.1002/bcp.70589
Vancouver
Yokokawa A, Shimazaki H, Igarashi S, Tagawa Y, Hisada N, Shibasaki H. Endogenous melatonin partial metabolic clearance as a potential endogenous marker of CYP1A2 activity. British Journal of Clinical Pharmacology. 2026;92(8):2899-2908. doi:10.1002/bcp.70589
BibTeX
@article{Yokokawa2026,
author = {Yokokawa, Akitomo and Shimazaki, Hayato and Igarashi, Shunji and Tagawa, Yoshiki and Hisada, Naoki and Shibasaki, Hiromi},
title = {Endogenous melatonin partial metabolic clearance as a potential endogenous marker of CYP1A2 activity},
journal = {British Journal of Clinical Pharmacology},
year = {2026},
volume = {92},
number = {8},
pages = {2899--2908},
doi = {10.1002/bcp.70589}
}
EUVIMED